Moreover, recent elegant in vitro studies have shown that Jak inhibition using upadacitinib in contrast to TNF inhibition with adalimumab, reversed the induction of activated HLA-DR+CD90+ RA synovial fibroblasts by NK cell-derived IFNγ, indicating this disease-associated subpopulation as a therapeutic target of current biologics (129). The gene discussed is THY1; the disease is rheumatoid arthritis.